Portrazza
Chemical Name | necitumumab |
Dosage Form | Injection (intravenous; 800 mg/50 mL) |
Drug Class | Monoclonal antibodies |
System | Respiratory |
Company | Eli Lilly and Company |
Approval Year | 2015 |
Indication
- In combination with gemcitabine and cisplatin, for first-line treatment of patients with metastatic squamous non-small cell lung cancer.